Jump to content


Biomarker for Diffuse Scleroderma skin has been discovered!


Photo

Long-term survival of patients with pulmonary arterial hypertension (PAH).

PH prognosis

  • Please log in to reply
No replies to this topic

#1 Joelf

Joelf

    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,610 posts
  • Location:West Sussex

Posted 12 November 2014 - 11:33 AM

Long-term survival of patients with pulmonary arterial hypertension (PAH).

 

Patients with PAH who achieve recovery to WHO-FC I or II without use of intravenous epoprostenol have similar survival to those who reach the same WHO-FC with use of intravenous epoprostenol. BMC Research Notes, June 2014; 7: 359. (Also see: Pulmonary Hypertension Prognosis)

 

This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.


Jo Frowde
ISN Assistant Webmaster

SD World Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)